Presentation is loading. Please wait.

Presentation is loading. Please wait.

Flow of study participants

Published byἈριδαίος Ζάρκος Modified over 5 years ago

Similar presentations

Presentation on theme: "Flow of study participants"— Presentation transcript:

1 Flow of study participants
John J.P. Kastelein, et al. Circulation 2006;114:

2 Dosing and follow-up schedule
John J.P. Kastelein, et al. Circulation 2006;114:

3 Subject Demographics and Baseline Lipid Characteristics*
John J.P. Kastelein, et al. Circulation 2006;114:

4 Adverse Events Considered Related to Study Medication by Dosage
John J.P. Kastelein, et al. Circulation 2006;114:

5 Dose-dependent effect of ISIS 301012 on apoB levels
John J.P. Kastelein, et al. Circulation 2006;114:

6 Dose-dependent effect of ISIS 301012 on LDL cholesterol levels
John J.P. Kastelein, et al. Circulation 2006;114:

7 ApoB and LDL-C Levels by Mean Percent Change Relative to Baseline*
John J.P. Kastelein, et al. Circulation 2006;114:

Download ppt "Flow of study participants"

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165: 2264-2271.

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:1264-72.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:
Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.

Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:1556-1563.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
Kastelein JJ, et al. Circulation 2008;117:3002-9 On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.
Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;388-393.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:1851-1857.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
Study Flow Diagram Holvoet P, et al. JAMA 2008;299:2287-93 The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.

Study Flow Diagram Holvoet P, et al. JAMA 2008;299: The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.
Ridker PM, et al. Lancet 2009;373:1175-82. Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25.

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:
Westerweel PE et al. Eur Heart J 2008;29:

Westerweel PE et al. Eur Heart J 2008;29:
Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?
Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.
Flowchart of participant screening, enrollment, withdrawal, and protocol completion Asterisk indicates those with partial or missing data included in analyses.

Flowchart of participant screening, enrollment, withdrawal, and protocol completion Asterisk indicates those with partial or missing data included in analyses.
Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p
Behavior and Biology: The Basic Sciences for AHA Action

Behavior and Biology: The Basic Sciences for AHA Action
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Similar presentations

Ads by Google